IRIDEX (NASDAQ: IRIX) — Perfil da empresa, notícias e dados financeiros
IRIDEX develops laser-based medical systems for ophthalmology, focusing on glaucoma and retinal disease treatments.
IRIDEX
IRIDEX (NASDAQ:IRIX) specializes in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices, and consumable instrumentation for the ophthalmology market. The company's primary focus is on treatments for glaucoma and retinal diseases, aiming to improve the vision and quality of life for patients worldwide. Their product portfolio includes the flagship Cyclo G6 laser system for glaucoma treatment, alongside a wide range of probes and devices designed for various ophthalmic laser procedures. Through ongoing research and development, IRIDEX strives to advance the field of laser therapy and expand its product offerings to meet the evolving needs of clinicians and their patients.
Resumo
Operações
Produtos e/ou serviços de IRIDEX
- Cyclophotocoagulation systems for treating various stages of glaucoma, promoting effective and minimally invasive solutions.
- Retinal restoration products including laser systems and delivery devices aimed at comprehensive retinal treatments.
- Glaucoma treatment services offering innovative solutions for intraocular pressure management.
- Veterinary laser solutions designed for precise and safe treatments in animal eye care.
- Durable and disposable laser probes enhancing precision and safety in eye surgeries.
- Comprehensive training and support services for healthcare professionals, ensuring effective use of laser technologies.
equipe executiva do IRIDEX
- Scott A. ShudaExecutive Chairman
- Patrick MercerCEO, President & Director
- Romeo R. DizonChief Financial Officer
- Bassem BouHabibSVP of International Sales & Business Development
- Leigh SalvoHead of Investor Relations
Comunicados recentes
O que a IRIDEX (IRIX) comunicou ao mercado, do mais recente para o mais antigo.
- LULD halt | IRIXFato relevante
Principais indicadores financeiros
Resultados divulgados pela IRIDEX , em USD.
- Cap. de mercado
- 13,1 mi
- Receita (TTM)
- 51,6 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.2
- Dividend yield
- —
- Margem de lucro
- -6.9%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 52,7 mi | -2,6 mi | -4,4 mi | |
| 48,7 mi | -8,3 mi | -8,9 mi | |
| 51,9 mi | -10 mi | -9,6 mi | |
| 57 mi | -7,5 mi | -7,5 mi |